Dr Randall explains rationale for CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor trial

Dr Randall, a professor at UC Davis Comprehensive Cancer Center, discussed the clinical reasoning behind testing the selective CSF-1R inhibitor pimicotinib (ABSK021) for tenosynovial giant cell tumor (TGCT). He highlighted how TGCT, while not a high‑grade sarcoma, can be locally aggressive and cause significant pain, stiffness, and functional loss.

The conversation referenced safety and efficacy data emerging from the MANEUVER trial, which evaluated pimicotinib in patients with TGCT. Randall noted that recent advances allow systemic targeted therapy to modify disease biology and improve patient outcomes beyond traditional surgical approaches.

He emphasized that the diffuse variant of TGCT presents particular challenges due to its extensive joint involvement, making non‑surgical options especially valuable. The discussion underscored the potential of CSF-1R inhibition to address these unmet needs in orthopedic oncology.